Pharmacogenetic testing in the clinical management of schizophrenia: A decision-analytic model

Journal of Clinical Psychopharmacology

Volumn 25, Issue 5, 2005, Pages 427-434

  Perlis, Roy H ^a   Ganz, David A ^b   Avorn, Jerry ^c   Schneeweiss, Sebastian ^c   Glynn, Robert J ^c   Smoller, Jordan W ^a   Wang, Philip S ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ACUTE PSYCHOSIS; AGRANULOCYTOSIS; AKATHISIA; ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIFE EXPECTANCY; MODEL; PHARMACOGENETICS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SOCIAL ASPECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; PHARMACOGENETICS; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 25444513776     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000177553.59455.24     Document Type: Article

References (65)

1. Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med. 2003;348:553-556.
2. Nebert DW, Jorge-Nebert L, Vesell ES. Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. Am J Pharmacogenomics. 2003;3:361-370.
3. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004;161:780-796.
4. Masellis M, Basile VS, Ozdemir V, et al. Pharmacogenetics of anti-psychotic treatment: lessons learned from clozapine. Biol Psychiatry. 2000;47:252-266.
5. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473.
6. Albers LJ, Ozdemir V. Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. Curr Med Chem. 2004;11:297-312.
7. Morley KI, Hall WD. Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations. J Mol Med. 2004;82:21-30.
8. Lehman AF, Steinwachs DM. Translating research into practice: the schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24:1-10.
9. Anonymous, ed. Physicians' Desk Reference. 54th ed. Medical Montvale, NJ: Economics Company; 2000.
10. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
11. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82-91.
12. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet. 2000;355:1615-1616.
13. Arranz MJ, Munro J, Osborne S, et al. Difficulties in replication of results. Lancet. 2000;356:1359-1360.
14. Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. 2000;20:246-251.
15. Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology (Oxford). 2004;43:156-163.
16. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol. 2002;29:2507-2512.
17. Wang PS, Ganz DA, Benner JS, et al. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model. J Ment Health Policy Econ. 2004;7:77-85.
18. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
19. Statistics NCfH. Vital statistics of the United States, 1995. Volume II, mortality, part A, section 6: life tables. DHHS Publication No (PHS) 98-1147. Hyattsville, MD: US Dept HHS; 1998.
20. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry. 1991;36:239-245.
21. Meltzer HY, Fatemi H. Suicide in schizophrenia: the effect of clozapine. Clin Neuropharmacol. 1995;18:S18-S24.
22. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59(suppl 3):3-7.
23. Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999;156:990-999.
24. Kane JM, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. 1986;22:254-258.
25. Baldessarini RJ, Viguera AC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry. 1995;52:189-192.
26. Revicki DA, Luce BR, Weschler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry. 1990;41:850-854.
27. Glennie JL. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997.
28. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 1991;325:81-86.
29. Gold MR, Siegel JE, Russell LB, et al, eds. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
30. Marder SR. Antipsychotic medications. In: Schatzberg AF, Nemeroff CB, eds. Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998.
31. Anonymous, ed. Drug Topics Red Book. Montvale, NJ: Medical Economics Company; 1999.
32. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21:419-429.
33. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry. 1993;150:1630-1638.
34. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry. 1994;55(suppl B):161-165.
35. Anonymous. Available at: http://www.fda.gov/ohrms/dockets/ac/03/agenda/ 3959A1_Final.doc. US Food and Drug Administration Center for Drug Evaluation and Research. Accessed April 14, 2004.
36. Zhang M, Owen RR, Pope SK, et al. Cost-effectiveness of clozapine monitoring after the first 6 months. Arch Gen Psychiatry. 1996;53:954-958.
37. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry. 1996;57:337-345.
38. Anonymous. http://www.pgxlab.com/clin_order.htm#price. University of Louisville School of Medicine Pharmacogenetics Diagnostic Laboratory, 2004.
39. Anonymous. http://www.bcmgeneticlabs.org/cptcodes.html. Baylor College of Medicine Medical Genetics Laboratory, 2004.
40. Meisel C, Gerloff T, Kirchheiner J, et al. Implications of pharmacogenetics for individualizing drug treatment and for study design. J Mol Med. 2003;81:154-167.
41. Wolf CR, Smith G, Smith RL. Science, medicine, and the future: pharmacogenetics. BMJ. 2000;320:987-990.
42. Graham JD, Corso PS, Morris JM, et al. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health. 1998;19:125-152.
43. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369-390.
44. Schoenbaum M, Unutzer J, Sherbourne C, et al. Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial. JAMA. 2001;286:1325-1330.
45. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med. 1997;337:809-815.
46. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med. 1978;299:926-930.
47. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321:1371-1376.
48. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology. 1997;8:671-677.
49. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry. 1995;152:183-190.
50. Sharma T, Hughes C, Soni W, et al. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology (Berl). 2003;169:398-403.
51. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25:233-255.
52. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50:79-88.
53. Kane JM, Leucht S, Carpenter D, et al. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(suppl 12):5-19.
54. Griffin JP. The cost of adverse drug reactions. Adverse Drug React Toxicol Rev. 1997;16:75-78.
55. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-1205.
56. Lieberman JA, Yunis J, Egea E, et al. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry. 1990;47:945-948.
57. Dettling M, Schaub RT, Mueller-Oerlinghausen B, et al. Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics. 2001;11:135-141.
58. Lahdelma L, Ahokas A, Andersson LC, et al. Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. J Clin Psychopharmacol. 2001;21:4-7.
59. Dettling M, Cascorbi I, Roots I, et al. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-Jewish Caucasian sample. Arch Gen Psychiatry. 2001;58:93-94.
60. Williams-Jones B, Graham JE. Actor-network theory: a tool to support ethical analysis of commercial genetic testing. New Genet Soc. 2003;22:271-296.
61. Nuffield Council on Bioethics. Pharmacogenetics: ethical issues. Available at: http://www.nuffieldbioethics.org/filelibrary/pdf/pharmacogenetics_ report.pdf. Accessed April 14, 2004.
62. Williams-Jones B, Corrigan OP. Rhetoric and hype: where's the 'ethics' in pharmacogenomics? Am J Pharmacogenomics. 2003;3:375-383.
63. Melzer D, Raven A, Ling T, et al. Pharmacogenetics: policy needs for personal prescribing. J Health Serv Res Policy. 2005;10:40-44.
64. Smart A, Martin P, Parker M. Tailored medicine: whom will it fit? The ethics of patient and disease stratification. Bioethics. 2004;18:322-342.
65. Sachdev P. The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Schizophr Bull. 1995;21:451-461.